Myasthenia Gravis Market Share

Global Myasthenia Gravis Market Overview

The Myasthenia Gravis Market Size was valued at USD 1.1 billion in 2022 and is projected to grow from USD 1.3 Billion in 2023 to USD 1.61 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.3% during the forecast period (2023 - 2032). Increased healthcare spending, better healthcare infrastructure, an increase in autoimmune illnesses, and significant investments are the market drivers for myasthenia gravis.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

In September 2023, Recipharm and Ahead Therapeutics established a cooperation to jointly create an innovative treatment for myasthenia gravis, a rare autoimmune disease. Ahead Therapeutics is a Spanish biotechnology business that employs its exclusive technology to create therapeutic treatments for various autoimmune disorders. Recipharm will offer their knowledge in analytical and process development to support toxicological research. They will also manufacture lipid nanoparticles, following Good Laboratory Practice (GLP) standards, for encapsulating the active pharmaceutical ingredient, namely an antigen peptide. Recipharm also provides the capability to increase manufacturing operations in order to support the future commercialization of the medicine. Liposomes can effectively trigger antigen-specific immunological tolerance through the use of a biomimetic approach, thus stopping the autoimmune reaction.

UCB, a leading biopharmaceutical company, received clearance from the Japanese Ministry of Health, Labour, and Welfare (MHLW) in September 2023 for two of its drugs, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan). These drugs have received approval for treating generalized myasthenia gravis (gMG) in adult patients who have not responded adequately to corticosteroids or other immunosuppressants. Japan has been the first country to grant permission for both rozanolixizumab and lucoplan at the same time. For the first time, Japanese doctors and patients will have the opportunity to select between two new specialized drugs for treating generalized myasthenia gravis (gMG) offered by a single pharmaceutical business. This will offer distinct choices and flexibility. UCB has the chance to offer customized and innovative advantages to adult patients in Japan suffering from generalized myasthenia gravis (gMG) because of the company's esteemed team of Japanese medical and scientific experts, as well as its extensive experience in the field of neurology.

Myasthenia Gravis Market Trends

• Growing prevalence of myasthenia gravis to propel market growth

The prevalence of myasthenia gravis has considerably increased during the past few decades on a global scale. This rise may be a result of populations in both developing and developed nations becoming more aware of the ailment and receiving diagnoses at a higher rate. The market is expanding as a result of the countries' increasing reimbursement policies for the illness. Also, a study by the National Organization for Rare Diseases (NORD) found that there are probably 50,000 cases of myasthenia gravis in the United States, or 14 to 40 cases per 100,000 people. The prevalence of the illness is also believed to be 15 per 100,000 people in the U.K., and it has grown over time. Thus, this factor is driving the market CAGR for myasthenia gravis.

Figure 1: Prevalence of myasthenia gravis by age

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Furthermore, the age distribution of the population is another aspect that contributes to the market's expansion. In 2020, 20.6% of Europe's population, or more than one in five people, were 65 years of age or older, per the Eurostat study. Between 2010 and 2020, the proportion of people in Europe who are 80 or older is expected to rise significantly, from 5.9% to 14.6%. The incidence of the illness rises progressively with age, according to the MDPI Journal of Clinical Medicine. The age range of 60 to 89 is where the prevalence is highest. As a result, the prevalence of the disorder is increasing along with the population's average life expectancy.

However, as health care expenses and per capita income increase globally, there will likely be a greater demand for pricey therapies like intravenous immunoglobulin (IVIG) therapy and plasma exchange. Furthermore, governments in developing countries are spending a lot of money to upgrade their healthcare systems, which will probably increase access to healthcare. Cutting-edge medicines, technologies, and treatments will probably become more popular as a result. The market of myasthenia gravis will soon have more opportunity for IVIG and monoclonal antibody therapy. Thus, it is anticipated that this aspect will accelerate myasthenia gravis market revenue globally.

Myasthenia Gravis Market Segment Insights

Myasthenia Gravis Type Insights

The Market segmentation of Myasthenia Gravis, based on type, includes Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis and Transient Myasthenia Gravis. The joint replacement segment held the majority share in 2022 in the  Myasthenia Gravis Market data. Congenital myasthenia gravis is an inherited condition that often manifests as muscle weakness and exhaustion at or near birth or in early childhood. It occurs when neurotransmitters—chemicals that assist relay information between nerve cells and muscles—are improperly released and absorbed. The neuromuscular junction is mutated in congenital myasthenia syndromes (CMS), which are characterized by the fatigue and weakening of several muscle groups, frequently including the ocular muscles.

Myasthenia Gravis End User Insights

The Myasthenia Gravis Market segmentation, based on end user, includes Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations. The hospitals and clinics segment dominated the market growth for myasthenia gravis in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030 driven by a broad patient pool's accessibility and escalating demand for superior MG treatment technology in diverse hospital settings. Furthermore, a large number of patients have visited medical facilities for MG diagnosis and treatment due to the availability of a variety of therapeutic options. Increasing investment in cutting-edge healthcare infrastructure is another important aspect boosting demand for the market.

Figure 2:  Myasthenia Gravis Market, by End User, 2022 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Myasthenia Gravis Regional Insights

By region, the study provides the market insights for myasthenia gravis into North America, Europe, Asia-Pacific and Rest of the World. North America myasthenia gravis market accounted for USD 0.4 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. The increased incidence of the ailment and the area's growing geriatric population will both have an impact on market growth in the upcoming years. Furthermore, both emerging and developing countries are more likely to be diagnosed with and treated for sickness thanks to the region's robust healthcare system and favorable reimbursement regulations.

Further, the major countries studied in the market report for myasthenia gravis are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  MYASTHENIA GRAVIS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe myasthenia gravis market accounts for the second-largest market share. This is due to increased financing and the creation of several healthcare organisations for the identification and management of rare diseases like myasthenia gravis. The European Joint Project on Rare Diseases was developed, according to a 2019 item in a national media in Europe, in order to find viable medicines and enhance diagnostics for uncommon disorders in connected EU member states. Further, the UK market of myasthenia gravis held the largest market share, and the Germany market of myasthenia gravis was the fastest growing market in the region.

Asia Pacific myasthenia gravis Market is expected to grow at the fastest CAGR from 2022 to 2030 ascribed to an increase in the prevalence of myasthenia gravis and the availability of better therapy payment rules, which are both boosting the frequency of diagnoses and raising the number of people receiving treatment. The activities tied to rising investments in the healthcare sector by the governments and manufacturers in the area are further drivers of growth. Moreover, China market of myasthenia gravis held the largest market share, and the India market of myasthenia gravis was the fastest growing market in the region.

Myasthenia Gravis Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of myasthenia gravis grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the myasthenia gravis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the global myasthenia gravis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, myasthenia gravis industry has provided medicine with some of the most significant benefits. The myasthenia gravis market major player such as GE Healthcare, Novartis AG, Boston Scientific Corporation, Grifols S.A., Koninklijke Philips N.V and Alexion Pharmaceuticals Inc.

Swiss global pharmaceutical company Novartis AG is headquartered in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. One of the biggest pharmaceutical firms in the world, Novartis was the fourth largest by sales in 2022 and has consistently been listed among the top five worldwide. In 2019, Innovative Medicines and Sandoz were the two business divisions that make up Novartis AG. Myasthenia gravis treatments are provided by the company's Innovative Medicines business area, which contributed US$37,714 million in revenue.

Boston Scientific Corporation ("BSC"), incorporated in Delaware, is a biomedical/biotechnology engineering company and a global manufacturer of medical devices used in interventional medical specialties, such as interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, vascular surgery, endoscopy, oncology, electrophysiology, cardiac surgery, urology, and gynaecology. Boston Scientific is well-known for creating the Taxus Stent, a drug-eluting stent that is used to unblock blocked arteries.

Key Companies in the market of myasthenia gravis includes

• GE Healthcare


• Novartis AG


• Boston Scientific Corporation


• Grifols S.A.


• Koninklijke Philips N.V.


• Alexion Pharmaceuticals Inc.

Myasthenia Gravis Industry Developments

November 2023: Argenx announces that the FDA has granted Priority Review status to its Investigational New Drug (IND) application for efgartigimod alfa-fcab, a neonatal Fc receptor (FcRn) blocker, for the treatment of generalized MG (gMG).October 2023: UCB Pharma announces that the FDA has accepted for review the New Drug Application (NDA) for zilucoplan, a subcutaneously delivered complement inhibitor, for the treatment of adults with acetylcholine receptor antibody positive (AChR-Ab+) gMG.September 2023: Janssen Research & Development, LLC announces that it has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of JNJ-69572529, an investigational anti-LINGO-1 antibody, in patients with gMG.August 2023: Immunovant Sciences GmbH announces that it has completed enrollment in its Phase 3 REMAP trial to evaluate the efficacy and safety of IMVT-1401, an investigational monoclonal antibody, in patients with gMG.July 2023: Horizon Therapeutics announces that it has received FDA approval for TEPEZZA (teprotumumab-trbw), an investigational thyrotropin receptor (TSHR) antagonist, for the treatment of adults with active generalized MG who are anti-acetylcholine receptor (AChR) antibody positive.

Myasthenia Gravis Market Segmentation

Myasthenia Gravis Type Outlook (USD Billion, 2019-2030)

• Ocular Myasthenia Gravis


• Congenital Myasthenia Gravis


• Generalized Myasthenia Gravis


• Transient Myasthenia Gravis

Myasthenia Gravis End User Outlook (USD Billion, 2019-2030)

• Hospitals and Clinics


• Diagnostic Centers


• Academic and Research Organizations

Myasthenia Gravis Regional Outlook (USD Billion, 2019-2030)

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America